Reading Time: 4 minutes

Company will highlight CorPath GRX capabilities in complex vascular
procedures

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus
Vascular Robotics, Inc.
(“Corindus” or the “Company”) (NYSE
American: CVRS), a leading developer of precision vascular robotics,
announced today that it will showcase advanced robotic capabilities of
the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24,
2019. Corindus will use the annual meeting at EuroPCR 2019 to highlight
recent milestones in technology development, including the latest CE
marked technIQ™ Smart Procedural Automation, automated movements aimed
at improving navigation, lesion crossing, and delivery of therapy.

The CorPath System is the world’s only U.S. Food and Drug Administration
(FDA) cleared and CE marked robotic platform for percutaneous coronary
intervention (PCI) and peripheral vascular intervention (PVI)
procedures. CorPath GRX received CE mark for neurovascular intervention
in April 2019, broadening the application of the system to treat all
vascular beds in the 33 countries that accept CE mark.

“As healthcare providers around the world continue to augment their
services with robotics, we are excited to showcase our latest
advancements of the CorPath GRX System at EuroPCR,” said Mark Toland,
President and Chief Executive Officer of Corindus. “We truly value the
opportunity to collaborate and engage with global, influential industry
leaders within the interventional community and we’re honored to take
part in EuroPCR for the first time.”

Jean Fajadet, M.D., Interventional Cardiologist at Clinique Pasteur in
Toulouse, France, PCR Vice-Chairman, and Course Director of EuroPCR,
oversaw the installation of CorPath GRX at Clinique Pasteur earlier this
year. The installation cemented the facility as the first site in all of
Europe to adopt the latest vascular robotic technology.

“Partnering with Corindus has allowed us to lead the movement of
vascular robotics in Europe,” said Jean Fajadet, M.D., Interventional
Cardiologist at Clinique Pasteur. “I am impressed with the capabilities
of CorPath GRX. The system’s ability to control the guiding catheter,
the guidewire, and the rapid exchange catheter (balloon or stent) is
critical to performing complex procedures. Furthermore, our procedure
rooms are equipped almost entirely with remote capabilities. From
imaging to procedural control, our physicians have access to essentially
everything they need from the control room.”

EuroPCR, which is the annual meeting of the European Association of
Percutaneous Cardiovascular Interventions, will celebrate its 30th
anniversary and will host more than 11,000 participants from across the
globe. For attendees interested in an exclusive opportunity to gain
firsthand experience with the latest smart procedural automation
technology available on the CorPath GRX System, register here
and visit Corindus at booth M49 through Friday, May 24, 2019.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath® platform
is the first FDA-cleared medical device to bring robotic precision to
percutaneous coronary and vascular procedures. CorPath GRX is the second
generation robotic-assisted technology offering enhancements to the
platform by adding important key upgrades that increase precision,
improve workflow, and extend the capabilities and range of procedures
that can be performed robotically. We are focused on developing
innovative robotic solutions to revolutionize treatment of emergent
conditions by providing specialized and timely medical care to patients
around the world. For additional information, visit www.corindus.com,
and follow @CorindusInc.

Forward-Looking Statements

Statements made in this release that are not statements of historical or
current facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of Corindus to be materially different from historical results or from
any future results or projections expressed or implied by such
forward-looking statements. Accordingly, readers should not place undue
reliance on any forward-looking statements. In addition to statements
that explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as “believes,” “belief,” “expects,” “estimates,”
“intends,” “anticipates” or “plans” to be uncertain and forward-looking.
Forward-looking statements may include comments as to Corindus’ beliefs
and expectations as to future events and trends affecting its business
and are necessarily subject to uncertainties, many of which are outside
Corindus’ control.

Examples of such statements include statements regarding or such as:

  • That Corindus will showcase advanced robotic capabilities of the
    CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24,
    2019;
  • Clinique Pastuer leads the movement of vascular robotics in Europe; and
  • The participants expected at the European Association of Percutaneous
    Cardiovascular Interventions.

Important factors that could cause actual results to differ materially
from those indicated by such forward-looking statements are described in
the sections titled “Risk Factors” in the Company’s filings with the
Securities and Exchange Commission, including its most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as
reports on Form 8-K, including, but not limited to the following: our
ability to expand our technology platform and achieve the advances
necessary for telestenting and remote procedures, including in humans;
our ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional and
other more complex cardiac interventions; obtaining necessary regulatory
approvals for the use on humans and marketing of our products in the
United States and in other countries, including for stroke and other
neurovascular interventions; the rate of adoption of our CorPath System
and the rate of use of our cassettes; risks associated with market
acceptance, including pricing and reimbursement; our ability to enforce
our intellectual property rights; our need for additional funds to
support our operations; our ability to manage expenses and cash flow;
factors relating to engineering, regulatory, manufacturing, sales and
customer service challenges; potential safety and regulatory issues that
could slow or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More information
is available on Corindus’ website at http://www.corindus.com.

Contacts

Corindus:
Media Contact:
Matter for Corindus
Jessica
Wolter
T: 978-518-4536
[email protected]
www.matternow.com

Investor Contact:
Lisa Wilson
In-Site Communications, Inc.
T:
917-543-9932
[email protected]